Alligator Bioscience

Alligator Bioscience is a pioneering biotech company founded in 2000 and is dedicated to researching and developing innovative immunotherapies for cancer. The company's slogan is "Pioneering advancements in immunotherapy with innovative drug candidates and proprietary technology platforms." Alligator focuses on advancing drug development candidates up to phase IIa clinical studies. Currently, Alligator’s pipeline includes three immune-modulating projects: ADC-1013, ADC-1015, and ADC-1016. Utilizing its proprietary technology platforms, ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a robust in vitro antibody optimization technology, Alligator continues to expand its research and development capabilities. The company secured its last investment of kr51.00M in a Venture Round on 29 May 2007 with investors including Home Capital AS and Malmsten Invest. Alligator Bioscience operates in the Biotechnology and Health Care industries.